AstraZeneca plc (AZN) Receives Neutral Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their neutral rating on shares of AstraZeneca plc (LON:AZN) in a report published on Sunday, April 30th. The brokerage currently has a GBX 4,500 ($58.09) price objective on the biopharmaceutical company’s stock, up from their previous price objective of GBX 4,200 ($54.21).

AZN has been the topic of a number of other reports. Liberum Capital restated a buy rating and issued a GBX 5,100 ($65.83) price objective on shares of AstraZeneca plc in a research note on Thursday, April 27th. Barclays PLC restated an overweight rating and issued a GBX 6,000 ($77.45) price objective on shares of AstraZeneca plc in a research note on Friday, April 28th. Berenberg Bank dropped their price objective on shares of AstraZeneca plc from GBX 5,500 ($71.00) to GBX 5,450 ($70.35) and set a buy rating on the stock in a research note on Tuesday, February 21st. Deutsche Bank AG restated a buy rating and issued a GBX 5,500 ($71.00) price objective on shares of AstraZeneca plc in a research note on Wednesday, March 15th. Finally, Societe Generale restated a buy rating on shares of AstraZeneca plc in a research note on Thursday, March 23rd. Five analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of GBX 5,001.80 ($64.56).

Shares of AstraZeneca plc (LON:AZN) traded down 0.41% on Friday, hitting GBX 5119.00. The stock had a trading volume of 2,921,092 shares. The company has a 50-day moving average of GBX 4,801.40 and a 200-day moving average of GBX 4,560.72. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The company’s market cap is GBX 64.81 billion.

ILLEGAL ACTIVITY NOTICE: “AstraZeneca plc (AZN) Receives Neutral Rating from JPMorgan Chase & Co.” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/05/19/jpmorgan-chase-co-boosts-astrazeneca-plc-azn-price-target-to-gbx-4500-updated-updated.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply